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To the Editor: 
Allergic rhinitis (AR) is the most common chronic inflamma-
tory disease, affecting an estimated 100 million Europeans (1). 
Despite a substantial burden on individuals, society and health 
economies (2), AR remains under-diagnosed, under-estimated 
(in terms of severity), and  under-treated (3). Although effective 
and safe treatments exist, patients wait too long to seek medical 
advice, often preferring to self-manage at drug stores and at 
the pharmacy (4). Other barriers to access of appropriate and 
effective AR treatment exist at patient, pharmacist and physician 
levels, including inability to recognize AR and diagnose it, inap-
propriate AR medication prescription/use (5), poor concordance 
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sive history and investigating signs and symptoms, confirmed 
(if necessary) by identification of sensitizing allergen(s) linked 
to symptoms (9). The patient is classified according to disease 
control and response to treatment using the AR VAS (retrospec-
tively, if VAS is not already routinely monitored). Approach to 
treatment is defined, including discussion of potential benefits 
of allergen avoidance (whenever possible) and other provoking 
triggers, saline nasal sprays/douching and available treatment 
options. Patient education is central at all stages (e.g. disease 
information, awareness of symptoms, importance of adherence 
and correct use of intranasal sprays). Patient participation in the 
decision-making process and in goal-setting is encouraged, and 
therapy matched to these goals and to patient preference. 
AR treatment is selected depending on type and history of 
patient, disease control (assessed by VAS) and point of care (i.e. 
pharmacy, GP or specialist) (Figure 2). 
Treatment Step 1: Patients with suspected AR presenting to 
any care provider. These patients should be treated with an 
intranasal corticosteroid (INS), non-sedating oral anti-histamine 
(OAH) or intranasal anti-histamine (INAH). Physicians’ clinical 
experience and patient symptoms, preferences and expectati-
ons, provoking triggers and co-morbidities should be taken into 
account for optimal outcomes.
Treatment Step 2: Patients who have tried and failed (i.e. VAS 
score ≥5/10 cm) Step 1 treatment at the pharmacy or previously 
at physician level. AR diagnosis should be confirmed, medicati-
on adherence checked, and co-morbidities evaluated. Treatment 
should be stepped up to fixed dose INS/INAH. Add-on therapy 
to INS is not recommended.
with AR treatment regimens and/or lack of awareness of new 
medications. There has, therefore, been a shift towards a more 
patient-centred approach to AR management, with a focus on 
personalized, predictive, preventative and participatory strate-
gies (6,7). The visual analogue scale (VAS) was introduced as the 
common language of AR control, improving patient-healthcare 
provider communication, and informing disease control status 
and treatment recommendations (8). However, guidelines based 
solely on VAS may not reflect the needs of physicians and 
patients in real-life, since VAS are not routinely used in every-
day practice and may not capture the profiles of all presenting 
patients. 
The European Forum for Research & Education in Allergy & 
Airway Diseases (EUFOREA) in collaboration with global key opi-
nion leaders in the field of chronic inflammatory airway disease, 
has developed an AR pocket guide with a treatment algorithm 
to expedite access to AR treatment and facilitate coordinated 
care. The algorithm is designed for real-life use. Its aim is simple: 
to improve AR knowledge and streamline the transition of 
patients between self-, pharmacy-, GP- and specialist-care, allo-
wing more coordinated care. The guide is practical and easy-to-
use in everyday clinical practice for any care provider. It is con-
cise and patient-centred, capturing every patient that attends 
the outpatient clinic of any care provider. This guide provides a 
‘what to do’ checklist when assessing AR patients, including a list 
of symptoms suggestive of AR, questions on suspected asthma, 
and instructions on how to use the AR VAS. The AR pocket guide 
is implemented in 5 easy steps: (i) diagnose AR, (ii) classify pa-
tients, (iii) define therapy, (iv) select product, and (v) activate tre-
atment plan (Figure 1). Diagnosis involves taking a comprehen-
Figure 1. EUFOREA allergic rhinitis pocket guide implementation pathway. AR: allergic rhinitis; European Forum for Research & Education in Allergy & 
Airway Diseases; VAS: visual analogue scale.
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lized treatment plan by prescribing medication and explaining 
the expected response and treatment duration with the patient 
(Figure 1). It is essential that physicians explain the criteria for a 
return clinic visit (e.g. sustained VAS score ≥5/10, adverse event). 
Use of digital technology to support adherence and to evaluate 
disease control may be suggested. A patient review (actual or 
digital) should be scheduled. If AR remains uncontrolled (i.e. 
sustained VAS score ≥5/10 cm) despite completion of the imple-
mentation pathway (Figure 1), then AR needs to be re-classified, 
therapy re-defined, product re-selected and the treatment plan 
fine-tuned. The aim is to devise a treatment plan (with patient 
collaboration) which provides AR control, a treatment response 
acceptable to the patient, suitable for long-term implementa-
tion and in compliance with patient needs.
The EUFOREA AR pocket guide with novel treatment algorithm 
designed for use in real-life, is concise, simple to use, suitable for 
all stakeholders including pharmacists, primary care physicians, 
ENT doctors, pulmonologists, allergists and paediatricians, and 
provides evidence-based and expert-endorsed AR management 
recommendations. This practical guide has the potential to 
ensure timely access to AR treatment, taking us one step closer 
to precision medicine, delivering the right treatment to the right 
Figure 2. EUFOREA allergic rhinitis pocket guide treatment algorithm. AR: allergic rhinitis; VAS: visual analogue scale.
Treatment Step 3: Patients who have tried and failed Step 2 
treatment (VAS remains ≥5/10 cm) or those who present with 
severe symptoms. AR diagnosis should be (re-)evaluated, and 
symptom-directed add-on therapies to fixed dose INS/INAH 
considered (e.g. ipratropium, leukotriene receptor antagonist; 
non-sedating OAH, ocular anti-histamine/cromone and nasal/
oral decongestant (≤7 days)) (Figure 2). Other Step 3 treatment 
options to consider include allergen-specific immunotherapy 
(AIT), short course OCS and surgery (for those with severe phar-
macological therapy-resistant nasal obstruction), at physicians’ 
discretion, considering availability, and risk/benefit ratio. 
AIT (subcutaneous or sublingual) is recommended for those 
patients looking for a sustained reduction of their rhinitis 
symptoms (if available and if appropriate to the patient’s 
sensitization pattern, and their preference, lifestyle, adherence 
history and comorbidities (e.g. asthma)). AIT may be considered 
for patients with uncontrolled moderate-to-severe AR (+/- con-
junctivitis) linked to exposure to allergens, with a confirmed IgE 
sensitization to these allergens and with inadequate control of 
symptoms despite pharmacotherapy and allergen avoidance 
measures and/or unacceptable adverse effects of medication.
The next step involves the design and activation of a persona-
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patient at the right time.
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